Cedars-Sinai Medical Center
Hematology and Oncology fellowship · Los Angeles, CA · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is Cedars-Sinai Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Cedars-Sinai Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from Cedars-Sinai Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
200
works per year
26th of 74 hematology and oncology fellowship programs
+26.9%
2-year growth
15th of 74 hematology and oncology fellowship programs
27.7%
in top 10% of field (works before 2025)
22nd of 72 hematology and oncology fellowship programs
46.4%
cited above world average
24th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 831Hematology · 158
Hematology and Oncology research topics at Cedars-Sinai Medical Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 205
- Pancreatic and Hepatic Oncology Research 104
- Multiple Myeloma Research and Treatments 96
- Cutaneous Melanoma Detection and Management 70
- CAR-T cell therapy research 64
- Cancer survivorship and care 61
- Global Cancer Incidence and Screening 28
- PARP inhibition in cancer therapy 27
Most cited at Cedars-Sinai Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber et al. · The Lancet · 2024 · PubMed · cited 958
- CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A. Reiss et al. · Nature Medicine · 2025 · PubMed · cited 270
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upTeresa Maria Santos Amaral et al. · Annals of Oncology · 2024 · PubMed · cited 232
- Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancerStephen Lawrence Shiao et al. · Cancer Cell · 2024 · PubMed · cited 212
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen Mary O'Reilly et al. · New England Journal of Medicine · 2026 · PubMed · cited 166
- Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021Pojsakorn Danpanichkul et al. · Gut · 2024 · PubMed · cited 165
- Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trialAndrea J. Bullock et al. · Nature Medicine · 2024 · PubMed · cited 159
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 studyGeorgina Venetia Long et al. · Annals of Oncology · 2024 · PubMed · cited 131
- Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Suzanne Lopez et al. · Nature Medicine · 2025 · PubMed · cited 129
- Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomasMarina T. Broz et al. · Nature Communications · 2024 · PubMed · cited 119